{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-166938","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2024-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.072703+00:00","generated_at":"2026-06-01T02:36:33.004102+00:00","sec_items":["5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"AN2 Therapeutics shareholders elect directors, ratify PwC, approve officer exculpation amendment at 2024 annual meeting","bullets":["78.31% quorum with 23,360,239 shares represented; all three Class II director nominees elected.","Margaret FitzPatrick, Patricia Martin, Melvin Spigelman each received over 17.7M votes for.","PricewaterhouseCoopers LLP ratified as auditor: 23,344,330 for, 12,786 against.","Amendment to certificate of incorporation for officer exculpation approved: 18,416,318 for."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-166938","json":"https://secwatch.observer/filing/0001193125-24-166938.json","markdown":"https://secwatch.observer/filing/0001193125-24-166938.md","text":"https://secwatch.observer/filing/0001193125-24-166938.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000119312524166938/0001193125-24-166938-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000119312524166938/d860451d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:36:33.004102+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}